Universal Chimeric Antigen Receptors for T-Cell Cancer Therapy

This invention is a patient-specific "Universal" Chimeric Antigen Receptor T-cell therapy that uses CAR T cells which target a universal "flag", such as a peptide, protein, or small molecule. The "Universal" CAR T cells are linked to "adapter" molecules or particles which have been designed to bind to patient-specific T-cells.

Background:

Chimeric Antigen Receptor (CAR) T-cell therapy is a form of immunotherapy wherein T-cells are designed to attack cancer cells, currently used most often to treat blood or lymphatic cancers. This process is costly, time consuming, not possible for all patients, and can have very severe off-target effects.

Applications:

• Cancer immunotherapy

Advantages:

• Enables CAR T-cell therapy to be
  • Faster
  • Cheaper
  • More widely available
  • Safer
  • Better standardized
  • More flexible